Befejeződött2. fázis
Phase II Clinical Trial to Evaluate the Ongoing Pregnancy Rate With OXO-001 in IVF/ICSI With Donor Oocytes.
A legfontosabb adatok
- Ki végzi
- OXOLIFE
- Hol
- Csehország, Lengyelország és Spanyolország28 helyszín, 3 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 2. fázis
- Résztvevők
- 408 fő vett részt
- Kezdés
- 2021. szept. 1.
- Befejezés
- 2023. dec. 1.
- A vizsgálat típusa
- Beavatkozással járó, 3 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- OXO-001
- Placebo
- A regiszteradat frissítve
- 2024. november 12.
Ki vehet részt
- Életkor
- 18 év – 45 év
- Nem
- Csak nők
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 26 feltétel megnézéseKevesebb
Ki vehet részt
- Voluntary informed consent
- Infertile female subjects indicated for egg donor programme in the context of ART
- Subjects aged ≥ 18 to ≤ 45 years at screening
- Body mass index (BMI) ≥ 18.0 and < 30.0 kg/m2
- Normal results of a 2-dimensional (2D) or 3-dimensional (3D) transvaginal US (TVUS) at screening
- Planned transfer of a fresh single blastocyst from a donated egg
- Good quality sperm
- Planned endometrial preparation and luteal support
Ki nem vehet részt
- History of two or more failed in-vitro fertilisation (IVF) / intra-cytoplasmic sperm injection (ICSI) cycles after embryo transfer of donor oocyte during the last attempts prior to the trial
- Endometrial biopsy or endometrial local injury within one month prior to screening
- Previous treatment with the IP of this trial at any time or participation in another clinical trial within the past 3 months prior to screening
- Abnormal haemorrhage of the reproductive tract of undetermined origin
- Positive hepatitis B surface antigen, hepatitis C virus antibody or human immunodeficiency virus results
- Systemic disease which might interfere with the purpose of the trial
- Any malignant neoplasm
- Known history of venous thrombosis or thromboembolism, including any coagulation abnormality leading to an increased risk of clotting
- History of uncontrolled hypertension
- Known hypersensitivity to any component of the IP used in this trial
- Known allergy, hypersensitivity or any other contraindications to preparations used in the context of endometrial preparation and fresh ET with a donated egg
- Any condition or treatment that, in the opinion of the investigator, may jeopardise the trial conduct according to the protocol
- Relevant clinically significant abnormality in the results of safety laboratory tests at screening
- Gynaecological abnormality relevant to the ART procedure and outcome, which in the opinion of the investigator could interfere with the trial objectives
- Diagnosis of severe endometriosis and/or adenomyosis
- History (within 12 months) of or known current problems with alcohol or substance abuse
- Employees of the investigator or trial centre, with direct involvement in the proposed trial or other studies under the direction of that investigator or trial centre, as well as family members of the employees or the principal investigator
- Persons committed to an institution by virtue of an order issued either by the judicial or other authorities
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
3 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The main objective of this clinical research trial is to test the efficacy of OXO-001 in a daily oral administration increasing the pregnancy rate in IVF/ICSI by preparing the uterus to receive the embryo.
A vizsgálat 3 csoportja
- OXO-001 200 mgA vizsgált kezelés
Two tablets of 100 mg have to be taken once daily in the early morning.
Kezelés: OXO-001
- OXO-001 300 mgA vizsgált kezelés
Two tablets of 150 mg have to be taken once daily in the early morning.
Kezelés: OXO-001
- PlaceboPlacebo, összehasonlításként
Two tablets have to be taken once daily in the early morning.
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Phase II, Randomised, Double-blind, Parallel-group, Placebo-controlled Trial to Assess Ongoing Pregnancy Rate With OXO-001 (200/300 mg) or Placebo at 10 Weeks Following Fresh Single Blastocyst Transfer From Donor Oocyte IVF/ICSI
- A regiszteradat frissítve
- 2024. november 12.